PL316259A1 - Treatment of diabetic nephropathy with valsartan - Google Patents

Treatment of diabetic nephropathy with valsartan

Info

Publication number
PL316259A1
PL316259A1 PL95316259A PL31625995A PL316259A1 PL 316259 A1 PL316259 A1 PL 316259A1 PL 95316259 A PL95316259 A PL 95316259A PL 31625995 A PL31625995 A PL 31625995A PL 316259 A1 PL316259 A1 PL 316259A1
Authority
PL
Poland
Prior art keywords
valsartan
treatment
diabetic nephropathy
nephropathy
diabetic
Prior art date
Application number
PL95316259A
Inventor
Gasparo Marc De
Nigel Levens
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4195481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL316259(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of PL316259A1 publication Critical patent/PL316259A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
PL95316259A 1994-03-17 1995-03-07 Treatment of diabetic nephropathy with valsartan PL316259A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH80094 1994-03-17
PCT/EP1995/000831 WO1995024901A1 (en) 1994-03-17 1995-03-07 Treatment of diabetic nephropathy with valsartan

Publications (1)

Publication Number Publication Date
PL316259A1 true PL316259A1 (en) 1997-01-06

Family

ID=4195481

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95316259A PL316259A1 (en) 1994-03-17 1995-03-07 Treatment of diabetic nephropathy with valsartan

Country Status (12)

Country Link
EP (1) EP0750500A1 (en)
JP (1) JPH09510225A (en)
CN (1) CN1143908A (en)
AU (1) AU1850695A (en)
BR (1) BR9507086A (en)
CA (1) CA2184712A1 (en)
CZ (1) CZ268896A3 (en)
FI (1) FI963611A0 (en)
HU (1) HUT76542A (en)
PL (1) PL316259A1 (en)
SK (1) SK117996A3 (en)
WO (1) WO1995024901A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT883401E (en) * 1996-02-29 2003-03-31 Novartis Ag AT1 RECEPTOR ANTAGONIST FOR APOPTOSIS STIMULATION
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
AU8996698A (en) * 1997-09-10 1999-03-29 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
EP1870098A3 (en) * 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN1304000C (en) * 1998-12-23 2007-03-14 诺瓦提斯公司 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating disease associated with increase of AT-1 or AT-2 receptors
NZ522953A (en) 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
DK1313714T3 (en) 2000-07-19 2008-12-15 Novartis Ag Valsartan salts
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (en) * 2000-08-22 2003-12-17 Novartis Ag A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ATTA RECEIVER ANTAGONIST AND A POTENTIATOR OF THE INSULIN SECRETION, THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PARTS KIT
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1454625A1 (en) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
AU2004289057A1 (en) * 2003-11-14 2005-05-26 Novartis Ag AT1-receptor antagonists for treating nephrotic syndrome
TR200703568A1 (en) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formulations
EP2405899A2 (en) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (en) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Non-steroidal antiinflammatory agents - for treatment of micro:vascular disease, e.g. diabetic retinopathy or diabetic nephropathy
DE19675036I2 (en) * 1990-02-19 2004-10-21 Novartis Ag Acyl compounds.
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
MX9603999A (en) 1997-12-31
SK117996A3 (en) 1997-03-05
CN1143908A (en) 1997-02-26
CA2184712A1 (en) 1995-09-21
HU9602536D0 (en) 1996-11-28
FI963611A (en) 1996-09-13
JPH09510225A (en) 1997-10-14
HUT76542A (en) 1997-09-29
FI963611A0 (en) 1996-09-13
EP0750500A1 (en) 1997-01-02
BR9507086A (en) 1997-09-16
CZ268896A3 (en) 1997-03-12
AU1850695A (en) 1995-10-03
WO1995024901A1 (en) 1995-09-21

Similar Documents

Publication Publication Date Title
PL337362A1 (en) Treatment of diabetes by means of thiazolydinone and metformin
GB9411080D0 (en) Treatment
PL316259A1 (en) Treatment of diabetic nephropathy with valsartan
EG21712A (en) Treatment of insulin resistance
EP0832204A4 (en) Treatment of insulin resistance
GB9405021D0 (en) Skin treatment composition
GB9606076D0 (en) Diabetes treatment
ZA973843B (en) Treatment of asthma with TNFR-lg.
GB9416410D0 (en) Effluent treatment
GB9415901D0 (en) Novel compounds and treatment
EP1126856A4 (en) Compounds and their therapeutic use with diabetic complications
GB9415900D0 (en) Novel compounds and treatment
ZA953237B (en) Medical treatment
ZA952120B (en) Skin treatment composition
NO963869D0 (en) Treatment of diabetic nephropathy with valsartan
GB9618290D0 (en) Treatment of diabetes
GB2285936B (en) Treatment of fluids
GB9410971D0 (en) Diabetes treatment
GB9609897D0 (en) Treatment of diabetes
GB2296238B (en) Improvements in or relating to effluent treatment
GB9412853D0 (en) Effluent treatment
GB9815149D0 (en) Treatment of diabetes
GB9812314D0 (en) Treatment of diabetes
GB2286824B (en) Wastewater treatment
GB9415920D0 (en) Novel compounds and treatment